Quipt Home Medical Achieves Positive Growth and Expands Reach with Strategic Acquisition

Quipt Home Medical ( (TSE:QIPT) ) just unveiled an announcement.

Quipt Home Medical reported its fiscal third quarter 2025 results, highlighting a return to positive organic growth with a 1.6% increase in quarter-over-quarter revenue, despite a year-over-year decrease. The company achieved an adjusted EBITDA of 23.5% of revenue and maintained strong recurring revenue at 81%. Operationally, Quipt expanded its reach through the acquisition of a durable medical equipment provider, enhancing its presence in the Appalachian Highlands region and securing a Preferred Provider Agreement with Ballad Health. This strategic move is expected to align the acquired operation’s margins with Quipt’s historical range, supporting long-term growth and stability.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Spark’s Take on TSE:QIPT Stock

According to Spark, TipRanks’ AI Analyst, TSE:QIPT is a Neutral.

Quipt Home Medical’s overall stock score is driven by strong revenue growth and cash flow management, despite profitability challenges. Technical indicators suggest stability, but valuation concerns due to negative earnings impact the score. The earnings call provided mixed insights, with strategic initiatives in place to address current challenges.

To see Spark’s full report on TSE:QIPT stock, click here.

More about Quipt Home Medical

Quipt Home Medical Corp. is a U.S.-based provider of home medical equipment, specializing in end-to-end respiratory care. The company focuses on delivering comprehensive respiratory solutions and services to patients across the United States.

Average Trading Volume: 43,518

Technical Sentiment Signal: Sell

Current Market Cap: C$127.7M

Find detailed analytics on QIPT stock on TipRanks’ Stock Analysis page.